Roche claims the success of a confirmatory study on Hemlibra

In particular, the substance has once again demonstrated its effectiveness in limiting bleeding requiring treatment in patients with coagulation factor VIII inhibitors.

The Rhine-based Roche laboratory claims to have observed indications in a phase IIIb clinical study confirming the safety and benefit profile of its treatment against hemophilia A Hemlibra (emicizumab). In particular, the substance has once again demonstrated its effectiveness in limiting bleeding requiring treatment in patients with coagulation factor VIII inhibitors.

Nearly one in three patients with hemophilia A develops factor VIII inhibitors, further increasing the risk of frequent and potentially fatal bleeding, underlines the report of a presentation to a specialized congress broadcast on Monday.

Hemlibra is already approved for this indication in around 100 countries.

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.